Clinical trials: Lipodystrophy
HIV
Eplerenone in HIV Associated Abdominal Fat Accumulation
The purpose of this study is to test the effects of a drug, eplerenone, along with lifestyle modification to affect sugar metabolism, body fat distribution, and cardiovascular health in HIV-infected individuals.
- Trial name
- NCT01405456
- Testing
- Eplerenone and lifestyle
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
HIV Infections, HIV Lipodystrophy Syndrome
Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
The aim of this trial is to evaluate the impact on fat distribution of switching to NRTI-sparing regimens in lipoatrophic antiretroviral experienced patients with complete viral suppression.
- Trial name
- NCT00122655
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors
- Where
- France
- Volunteers
- 100 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HAART-induced Lipodystrophy and Metabolic Syndrome
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
The purpose of this study is to examine whether replacing leptin to normal levels can reverse the changes in fat distribution, lipid profile, and other metabolic problems associated with highly active antiretroviral therapy…
- Trial name
- NCT00140244
- Testing
- r-metHuLeptin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
HIV Infections, Lipodystrophy
Raltegravir Therapy for Women With HIV and Fat Accumulation
Ritonavir-boosted protease inhibitor (PI) regimens have become a backbone for treatment of people with HIV. However, adverse drug effects, particularly lipodystrophy/lipoatrophy are closely associated with these regimens.
- Trial name
- NCT00656175
- Testing
- raltegravir
- Where
- 5 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- University of California, Los Angeles
HIV Infections
Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir
The objective is to analyse the changes in the adipose tissue hystological features and the adipogenesis gene expression and related to inflammation after 48 and 96 weeks after the change from AZT+3TC+ABC (Trizivir®) to a…
- Trial name
- BIOKAL (NCT01031849)
- Testing
- Kaletra
- Where
- 2 sites in Spain
- Volunteers
- 7 people
- Sponsor
- Ines Perez
HIV Infections, Dyslipidemias
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose…
- Conditions
- HIV Infections, Dyslipidemias, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT00192621
- Testing
- Combivir (zidovudine [AZT] / lamivudine [3TC]), Kaletra (lopinavir [LPVr])
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Prostate Cancer, Renal Cancer
64Cu-GRIP B in Patients With Advanced Malignancies
This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET)…
- Conditions
- Prostate Cancer, Renal Cancer, Urethral Cancer, Advanced Solid Tumor
- Trial name
- NCT05888532
- Testing
- Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Rahul Aggarwal
Diabetes Mellitus
for Adipose Tissue DIabetes VAriants (fATDIVA)
The adipose (fat) cells under the skin are where individuals store excess fat. The more excess fat they have, the more "strain" they put on these cells which then get bigger and don't work as well as they should.
- Trial name
- fATDIVA (NCT02505321)
- Testing
- Oral Triglyceride Tolerance Test (OTTT), Abdominal fat biopsy (optional)
- Where
- United Kingdom
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Familial Partial Lipodystrophy
The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in a randomized treatment (RT) period in participants with familial partial lipodystrophy (FPL).
- Trial name
- NCT02527343
- Testing
- volanesorsen
- Where
- 12 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Akcea Therapeutics
Nasolabial Folds, Lipoatrophy
Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
This Phase 1, randomized, placebo-controlled, double-blind, healthy volunteer study tested the safety, tolerability, and plasma pharmacokinetics of two different concentrations of TAT4 Gel administered once daily to 50 cm2 of…
- Conditions
- Nasolabial Folds, Lipoatrophy, Lipodystrophy
- Trial name
- NCT02647853
- Testing
- TAT4 Gel concentration A, TAT4 Gel concentration B
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Topokine Therapeutics, Inc.
Hepatic Steatosis
Cholic Acid for Hepatic Steatosis in Lipodystrophy
To evaluate the efficacy and safety of cholic acid therapy in treating lipodystrophy patients with hepatic steatosis. This is a randomized, double-blind, placebo-controlled cross-over study.
- Trial name
- NCT00457639
- Testing
- Cholic Acid
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Lipodystrophy
Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue
A previous study substituting zidovudine or stavudine to abacavir in patients with severe or moderate lipoatrophy has shown an increase in limb fat by DEXA.
- Trial name
- RAVE (NCT00647946)
- Testing
- tenofovir DF, abacavir 300mg twice daily
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and…
- Conditions
- Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
- Trial name
- NCT04517253
- Testing
- Baricitinib
- Where
- 5 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Skin Aging, Facial Wrinkles
Study of the Subdermal Implant "Ultracol"
Study of the effectiveness of the medical device "Intradermal implant, sterile ULTRACOL based on polydioxanone (ULTRA V Co., Ltd., Korea) in the correction of skin contour defects.
- Conditions
- Skin Aging, Facial Wrinkles, Senile Skin Atrophy, Lipodystrophy
- Trial name
- NCT07617350
- Testing
- Administration of the prepared solution - 1 time Post injection observation - 30, 60, 160 days from the date of the first injection.
- Where
- Russia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Estelab Clinic
Lipodystrophy Acquired, Lipodystrophy Congenital
Registry for Patients With Lipodystrophy
Given the lack of knowledge on lipodystrophies, the medical and social responsibility for the persons affected by it calls for the monitoring of the progression over long periods of time.
- Trial name
- ECLip Registry (NCT03553420)
- Where
- 28 sites in Austria, France and 14 more
- Volunteers
- 5,000 people
- Sponsor
- University of Ulm
Cushing's Syndrome
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease.
- Trial name
- NCT03817840
- Testing
- Treatment of Cushing's
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Familial Partial Lipodystrophy, Hypertriglyceridemia
Study of Gemcabene in Adults With FPLD
The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg daily for 12 weeks) in up to eight…
- Conditions
- Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03508687
- Testing
- 300mg Gemcabene, 600mg Gemcabene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Elif Oral
Lipodystrophy, Metabolic Syndrome
Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances
To evaluate the prevalence of lipodystrophy syndrome in patients receiving currently available antiretroviral drugs, and the prevalence of associated metabolic syndrome in HIV-infected patients with a previous diagnosis of…
- Trial name
- METALIP (NCT02614027)
- Testing
- Evaluation of metabolic syndrome, Evaluation of changes in fat by DXA while on current therapy
- Where
- Spain
- Volunteers
- 276 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
Generalized Lipodystrophy
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on…
- Trial name
- NCT04159415
- Testing
- Low-Dose REGN4461, High-dose REGN4461
- Where
- 8 sites in United States, Peru and 2 more
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals